Wise, J. (2016) BMJ.355:i5472
Dapagliflozin (marketed as Forxiga) has been recommended as part of triple therapy for patients with type 2 diabetes, giving doctors another prescribing option for patients with uncontrolled blood sugar.
Draft guidance from the National Institute for Health and Care Excellence (NICE) has recommended dapagliflozin in combination with metformin and a sulfonylurea as an option for treating type 2 diabetes in adults. NICE said that it had fast tracked appraisal of the drug so that final guidance could be published sooner and benefit people more quickly.
Dapagliflozin is already recommended as monotherapy when metformin is contraindicated and as dual therapy with metformin. It is a selective sodium glucose cotransporter 2 (SGLT-2) inhibitor, which blocks reabsorption of glucose in the kidneys and promotes excretion of excess glucose in the urine. Two other drugs in the same class, empagliflozin and canagliflozin, are already recommended for triple therapy.
The clinical experts said that in addition to lowering HbA1c, SGLT-2 inhibitors also lowered blood pressure. Another benefit of the SGLT-2 inhibitors was weight loss, they said. This is particularly important given the strong association between type 2 diabetes and excess body weight, and some treatments, such as insulin, can also result in weight gain.
Read the full commentary here
Read the draft NICE guidance here